Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
February 7, 2024 – Biotechnology – BRCA gene testing, Informed Genomics, oncology
7 February 2024 — Birmingham, UK — NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry a genetic fault that can increase the risk of developing some cancers.
The NHS Jewish BRCA Testing Programme is part of the NHS’ major drive to detect cancer early when it is easier to treat. The programme, which will run over three years, will see anyone over the age of 18 with Jewish ancestry offered a simple genetic saliva test to look for the presence of BRCA1 or BRCA2 faults, which increases the likelihood of developing certain cancers, including breast, ovarian, prostate and pancreatic cancer.
It is estimated that a fault in one of the BRCA genes affects around one in 40 Jewish people compared with one in 250 in the general population. Up to four in 10 ovarian cancers and one in 10 breast cancers in the Jewish community are caused by a BRCA mutation, but 90% of Jewish BRCA carriers are unaware they carry it.
The saliva samples will be carried out at home and then be sent to labs for testing, including Informed Genomics Limited’s UKAS ISO 15189 accredited cancer genetic testing lab, which will use Illumina’s sequencing technology to process up to 1,000 samples each month.
Commenting on Informed Genomics’ involvement in the programme, Chief Executive Officer Simon Davis said: “We’re delighted to support NHS England in this landmark programme, being the only private lab brought on board to increase capacity to meet the demand seen in pilot programmes in a cost-effective and efficient way. This programme epitomises our mission to provide accessible genomic testing, enabling earlier diagnosis, personalised treatments and improved patient outcomes.”
Full information on the NHS Jewish BRCA Testing Programme can be found here.
About Informed Genomics
Informed Genomics (IGL) have a wealth of experience in providing both clinical and translational genomics services. IGL are passionate about making testing accessible to patients and dedicated to providing services that make a meaningful and actionable impact on an individual’s healthcare journey. IGL’s sequencing services includes liquid and tumour biopsy, whole exome and custom panel design. IGL also launched their Hereditary Cancer Susceptibility Service (HCSS) offering a full sample to report testing service for clinicians and researchers. At IGL we place quality at the heart of everything we do. The patient is our priority and we strive to provide the right testing that has a meaningful impact on an individual’s healthcare experience and outcomes. We are focused on providing innovative testing solutions that can empower an individual in their healthcare choices. Visit: informedgenomics.com.
